Clinical Trial Update: Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

View source ↗

Summary

This is a clinical trial update about using a CD20 antibody plus cytokine-induced killer (CIK) cells to treat refractory lymphomas. The current status is not pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: Han weidong | Conditions: Lymphomas | Status: UNKNOWN